Evidence map›Paper›PMID 34830762›Full record

ArticleCancers2021

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.

Hagop M Kantarjian, Gerhard Zugmaier, Monika Brüggemann, Brent L Wood, Heinz A Horst, Yi Zeng, Giovanni Martinelli

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02000427 phase2completednot on this map

A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)

TypeinterventionalSponsorAmgenRan2014 to 2017Enrolled45ConditionsRelapsed/Refractory Philadelphia Positive B-precursor ALLArmsBlinatumomab
NCT02013167 phase3terminatednot on this map

A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)

TypeinterventionalSponsorAmgenRan2014 to 2017Enrolled405ConditionsRelapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaArmsBlinatumomab, Standard of Care Chemotherapy
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Hagop M KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Gerhard ZugmaierAmgen Research (Munich) GmbH, Staffelseestraße 2, 81477 Munich, Germany.
Monika BrüggemannDepartment of Hematology, University Hospital of Schleswig-Holstein, 24105 Kiel, Germany.
Brent L WoodDepartment of Hematopathology, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA 90007, USA.
Heinz A HorstDepartment of Internal Medicine II, University Hospital of Schleswig-Holstein, 24105 Kiel, Germany.
Yi ZengAmgen Inc., Thousand Oaks, CA 91320, USA.
Giovanni MartinelliIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.ORCID 0000-0002-1025-4210
University Hospital Schleswig-Holstein · DEAmgen (Germany) · DEAmgen (United States) · USIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITThe University of Texas MD Anderson Cancer Center · USUniversity of Southern California · US

Funding

Amgen Inc. Not applicableAstellas Pharma, Inc. Not applicable
6 · The paper itself

Abstract

Association of blinatumomab treatment with myelosuppression was examined in this study. Peripheral blood counts were assessed prior to, during, and after blinatumomab treatment in patients with relapsed/refractory Philadelphia chromosome-negative (Ph-) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL;

Indexed as

acute lymphoblastic leukemiabispecific antibodybispecific T-cell engagerblinatumomabmeasurable residual diseasemyelosuppression

Identifiers

PMID34830762
PMCPMC8616108
OpenAlexW3211928898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.